New immunotherapy cocktail aims to stall pancreatic cancer after chemo

NCT ID NCT07199764

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a combination of two immunotherapy drugs, odetiglucan and mitazalimab, as a maintenance treatment for people with unresectable pancreatic cancer that has not worsened after 4-8 months of standard chemotherapy. The study will enroll 100 adults and measure how long the cancer stays under control. The goal is to see if this approach can delay disease progression and improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Odetiglucan and mitazalimab (two immunotherapy drugs given together intravenously every 3 weeks)
What this could lead to
If successful, this could offer a new maintenance treatment option to help keep pancreatic cancer from growing after initial chemotherapy.
What could go wrong
This is an early Phase 2 trial with only 100 participants and no comparison group, so results may not apply broadly. Immunotherapy can cause serious immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital of the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.